Researchers from Novo Nordisk Inc. Publish Findings in Obesity [Semaglutide 2.4 mg clinical outcomes in patients with obesity or overweight in a real-world setting: A 6-month retrospective study in the United States (SCOPE)].

A recent study conducted by researchers from Novo Nordisk Inc. examined the effectiveness of semaglutide 2.4 mg in reducing body weight and improving cardiometabolic parameters in adults with overweight or obesity in a real-world clinical practice setting. The study found that after 6 months of treatment, patients experienced a significant mean body weight reduction, as well as improvements in biomarkers such as blood pressure and HbA1c. These findings support previous clinical trials and suggest that semaglutide may be an effective therapeutic option for obesity. The study was published in Obesity Science & Practice. [Extracted from the article]